Taiho Oncology and Taiho Pharmaceutical Announce FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax for AML Patients,PR Newswire Healthring
Taiho Oncology and Taiho Pharmaceutical Announce FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax for AML Patients [City, State] – July 9, 2025 – Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd. today announced a significant milestone in the treatment of acute myeloid leukemia (AML) with the U.S. Food and … Read more